Scientists show key role for inflammation in Alzheimer's

August 14, 2013
Scientists show key role for inflammation in Alzheimer’s
Scientists show key role for inflammation in Alzheimer’s.

Southampton scientists have found that an immune response in the brain plays a key role in the development of Alzheimer's, and that a vaccine designed to tackle the disease was able to suppress the response.

The findings culminate a decade of research following up on a phase I trial of the vaccine, funding by Alzheimer's Research UK and Medical Research Council (MRC). A subsequent, phase II trial was halted when some developed inflammation – but the University of Southampton team believes the findings suggest the trial may have been more successful if performed earlier in the disease process.

Published in the journal Brain online today (Wednesday 14 August), the new findings come after the team examined from people who took part in a clinical trial of the AN1792 vaccine over a decade ago. The trial, which involved people with mild to moderate stage Alzheimer's disease, was designed to test the safety of AN1792, which aimed to remove the – a key component of the disease – from the brain.

A phase II trial of the vaccine was halted in 2002 when a small number of participants developed , and results from the trial showed no improvement in people's symptoms. Since then, researchers led by a team at Southampton have been working to fully understand the effects of the treatment on the people who took part in the original phase I safety trial. Crucially, the researchers were granted access to the data from this trial, and a number of participants from the trial volunteered to take part in follow-up assessments with the team, with many of them signing up to donate their brains to be studied after their deaths.

Earlier research from the team showed that although the vaccine did not improve people's symptoms, it did successfully remove amyloid from their brains. They showed that the vaccine worked by activating in the brain, called microglia, to remove amyloid – sparking a theory that the treatment may have over-activated the immune response and further contributed to the participants' decline. In the latest study, the researchers set out to get a more detailed picture of how microglia are activated during Alzheimer's, and how these cells responded to treatment with AN1792.

The team compared brain tissue from 11 people who took part in the trial and 28 people with Alzheimer's who were not part of the trial, investigating the levels of different markers of inflammatory processes in the brain. They discovered that in the brains of people who had not been treated, inflammation was linked to higher levels of a second protein, tau, which also builds in the brain during Alzheimer's – suggesting that inflammation was a key part of the disease process.

In contrast, brain tissue from those who had been given the vaccine showed fewer signs of inflammation. The results suggest that although the treatment initially activated the brain's immune response in order to remove amyloid from the brain, this was later suppressed – minimising potential long-term damage that may have been caused by over-activity of the immune system.

Dr Delphine Boche, Senior Lecturer in Clinical Neurosciences at the University of Southampton and a co-author of the study, said:

"Our study not only adds to existing evidence that inflammation in the brain plays an important role in Alzheimer's disease, but provides new hope for future . Our research shows that amyloid can be removed from the brain without over-activating the brain's immune system in the long-term, and this provides some hope for anti-amyloid treatments of the future. We believe that amyloid acts as an early 'trigger' for Alzheimer's, and it may be that drugs targeting amyloid will need to be trialled earlier in the disease process in order to be successful.

"We believe inflammation helps trigger Alzheimer's, rather than being a response to the disease process, and our next step will be to investigate this theory further. A fuller understanding of the role of the different inflammatory processes identified here could help guide potential new treatments for Alzheimer's. Our results also underline the value in continuing to follow up the results of trials like this one, and we're hugely grateful to the volunteers who continued to take part in research and helped make our study possible."

Dr Simon Ridley, Head of Research at Alzheimer's Research UK, said:

"By continuing to follow up the participants of this trial, this team has ensured that important data from what could have been dismissed as a failed clinical trial has not been lost. We're delighted to have supported this study, which has shed new light on some of the inflammatory processes involved in Alzheimer's – the first step on the road to new treatment design. By examining the brain's response to this particular anti-amyloid treatment, this study could also help guide future trials of other treatments designed to remove amyloid from the brain. The results also add further weight to the importance of early intervention with drug treatments for Alzheimer's, when they are likely to be more effective. For promising results like these to translate into benefits for people with Alzheimer's, it's crucial that we continue investing in research."

Professor Paul Bolam, member of the Neurosciences and Mental Health funding board at The Medical Research Council, said:

"The better we understand the relationship between the immune system and the processes in the brain, the more equipped we will be to develop new treatments that can be implemented at an earlier stage. This study also highlights the importance of maximising data from all clinical , not just those that report a positive outcome."

The paper "Inflammatory components in human Alzheimer's disease and following active A?42 immunisation" is published in the Oxford University Press journal Brain (DOI: 10.1093/brain/awt210).

Explore further: Researchers investigate mechanism of Alzheimer's therapy

Related Stories

Researchers investigate mechanism of Alzheimer's therapy

July 8, 2013
Researchers at the University of Kentucky Sanders-Brown Center on Aging, led by faculty member Donna Wilcock, have recently published a new paper in the Journal of Neuroscience detailing an advance in treatment of Alzheimer's ...

New Alzheimer's research suggests possible cause: The interaction of proteins in the brain

June 19, 2013
For years, Alzheimer's researchers have focused on two proteins that accumulate in the brains of people with Alzheimer's and may contribute to the disease: plaques made up of the protein amyloid-beta, and tangles of another ...

Alzheimer's vaccine triggers brain inflammation when brain amyloid burden is high

November 14, 2011
Patients with Alzheimer's disease who are in the early stages of their illness will likely benefit most from vaccine therapies now being tested in a number of human clinical trials, say researchers from Georgetown University ...

Vaccine trial for Alzheimer's clears key hurdle

June 7, 2012
A vaccine which revives a promising but long-abandoned path to thwart Alzheimer's disease has cleared a key safety hurdle in human trials, researchers say.

New findings on the brain's immune cells during Alzheimer's disease progression

April 11, 2013
The plaque deposits in the brain of Alzheimer's patients are surrounded by the brain's own immune cells, the microglia. This was already recognized by Alois Alzheimer more than one hundred years ago. But until today it still ...

Lack of immune cell receptor impairs clearance of amyloid beta protein from the brain

July 1, 2013
Identification of a protein that appears to play an important role in the immune system's removal of amyloid beta (A-beta) protein from the brain could lead to a new treatment strategy for Alzheimer's disease. The report ...

Recommended for you

Noninvasive eye scan could detect key signs of Alzheimer's years before patients show symptoms

August 17, 2017
Cedars-Sinai neuroscience investigators have found that Alzheimer's disease affects the retina—the back of the eye—similarly to the way it affects the brain. The study also revealed that an investigational, noninvasive ...

Could olfactory loss point to Alzheimer's disease?

August 16, 2017
By the time you start losing your memory, it's almost too late. That's because the damage to your brain associated with Alzheimer's disease (AD) may already have been going on for as long as twenty years. Which is why there ...

New Machine Learning program shows promise for early Alzheimer's diagnosis

August 15, 2017
A new machine learning program developed by researchers at Case Western Reserve University appears to outperform other methods for diagnosing Alzheimer's disease before symptoms begin to interfere with every day living, initial ...

Brain scan study adds to evidence that lower brain serotonin levels are linked to dementia

August 14, 2017
In a study looking at brain scans of people with mild loss of thought and memory ability, Johns Hopkins researchers report evidence of lower levels of the serotonin transporter—a natural brain chemical that regulates mood, ...

Alzheimer's risk linked to energy shortage in brain's immune cells

August 14, 2017
People with specific mutations in the gene TREM2 are three times more likely to develop Alzheimer's disease than those who carry more common variants of the gene. But until now, scientists had no explanation for the link.

Scientists reveal role for lysosome transport in Alzheimer's disease progression

August 7, 2017
Researchers from Yale University School of Medicine have discovered that defects in the transport of lysosomes within neurons promote the buildup of protein aggregates in the brains of mice with Alzheimer's disease. The study, ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.